Zacks Research Analysts Decrease Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research decreased their FY2026 EPS estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of $0.94 per share for the year, down from their previous estimate of $1.16. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The business had revenue of $207.64 million for the quarter, compared to the consensus estimate of $223.78 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. Corcept Therapeutics’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.41 earnings per share. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Several other research firms have also commented on CORT. HC Wainwright reissued a “buy” rating and issued a $145.00 price target on shares of Corcept Therapeutics in a research report on Tuesday. Wolfe Research began coverage on shares of Corcept Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Canaccord Genuity Group reissued a “buy” rating and set a $140.00 price target on shares of Corcept Therapeutics in a research report on Thursday, September 25th. Piper Sandler cut their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a research report on Friday, August 1st. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics currently has an average rating of “Hold” and a consensus price target of $135.25.

Corcept Therapeutics Stock Down 0.6%

Corcept Therapeutics stock opened at $79.80 on Thursday. The firm has a market cap of $8.39 billion, a P/E ratio of 70.62 and a beta of 0.43. The business has a fifty day moving average of $78.26 and a two-hundred day moving average of $74.03. Corcept Therapeutics has a twelve month low of $49.00 and a twelve month high of $117.33.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Corcept Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after purchasing an additional 587,053 shares during the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Corcept Therapeutics by 128.5% during the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 433 shares during the period. Coldstream Capital Management Inc. purchased a new stake in Corcept Therapeutics in the third quarter valued at approximately $242,000. Danske Bank A S purchased a new stake in Corcept Therapeutics in the third quarter valued at approximately $1,335,000. Finally, Advisory Services Network LLC acquired a new position in Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In other news, insider William Guyer sold 4,500 shares of Corcept Therapeutics stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $80.90, for a total transaction of $364,050.00. Following the completion of the sale, the insider directly owned 787 shares in the company, valued at approximately $63,668.30. The trade was a 85.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $73.99, for a total transaction of $1,479,800.00. Following the sale, the insider directly owned 7,904 shares in the company, valued at $584,816.96. This trade represents a 71.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 263,900 shares of company stock worth $20,373,338 in the last 90 days. 20.80% of the stock is owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.